Other pharmaceutical agents.
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D000986:Antisickling Agents / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D002273:Carcinogens / Q000009:adverse effects* / Q000737:chemistry; D002400:Cathartics / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D019317:Evidence-Based Medicine; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D007202:Indicators and Reagents / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D007408:Intestinal Absorption; D009369:Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D019384:Nucleic Acid Synthesis Inhibitors / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D020113:Phenolphthalein / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D012107:Research Design; D012307:Risk Factors; D014018:Tissue Distribution; D014812:Vitamin K / Q000009:adverse effects* / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use
D000970:Antineoplastic Agents; D000986:Antisickling Agents; D002273:Carcinogens; D002400:Cathartics; D007202:Indicators and Reagents; D019384:Nucleic Acid Synthesis Inhibitors; D014812:Vitamin K; D020113:Phenolphthalein; D006918:Hydroxyurea